A cadre of new biotechs have set their sights on targeting RNA with small-molecule drugs. Justin Petrone and Laura DeFrancesco report.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Rizvi, N.F. et al. ACS Chem. Biol. 13, 820–831 (2018).
Tran, T. & Disney, M.D. Nat. Commun. 3, 1125 (2012).
Rzuczek, S.G. et al. Nat. Chem. Biol. 13, 188–193 (2017).
Wang, J., Schultz, P.G. & Johnson, K.A. Proc. Natl. Acad. Sci. USA 115, E4604–E4612 (2018).
Mustoe, A.M. et al. Cell 173, 181–195.e18 (2018).
Palacino, J. et al. Nat. Chem. Biol. 11, 511–517 (2015).
Seiler, M. et al. Nat. Med. 24, 497–504 (2018).
Welch, E.M. et al. Nature 447, 87–91 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Petrone, J., DeFrancesco, L. Small molecules get the message. Nat Biotechnol 36, 787–790 (2018). https://doi.org/10.1038/nbt.4241
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4241